In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

It also involved in organogenesis, but the importance of signaling between the endothelium and surrounding cells has been unclear. In the February 7 Science, Jennifer LeCouter and colleagues from ...

FECD affects the corneal endothelial cells, which form a layer responsible ... how this mechanism plays out throughout human development to better understand when may be the most effective time ...

Earlier R&D work, coupled with successful development of ... cells on the front of the cornea. Such epithelial cells regenerate naturally, unlike their endothelial counterparts, but the healing ...

In 2022, doctors in Japan performed a transplant of iPS cell-derived corneal endothelial cells iPS cell derived-corneal endothelial cell transplants are injected and take about 20 minutes In Japan ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

According to the company, the implantation demonstrated significant improvements in both distance and near vision, with manageable safety outcomes and minimal impact on corneal endothelium cell ...